
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
Michael L. Wang, MD, discusses the updated results from the Phase 1/2 BRUIN clinical trial, which focused on the use of pirtobrutinib in previously treated mantle cell lymphoma.
OncLive® Rapid Readout from American Society of Hematology (ASH) 63rd Annual Meeting: Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study
Segment Description: Michael L. Wang, MD, discusses the updated results from the Phase 1/2 BRUIN clinical trial, which focused on the use of pirtobrutinib in previously treated mantle cell lymphoma. (
Segment Body Content:
Methods
Results
Conclusion






